Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. - Horwitz SM; Feldman TA; Ye JC; Khodadoust MS; Munoz J; Hamlin PA; Kim YH; Wilcox RA; Patel MR; Coffey G; Innes A; Betz A; et al. (Leukemia & lymphoma, 2025)